EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Delivering a commercial edge
Biopharma Launch Edge provides a comprehensive range of launch services designed to help deliver groundbreaking outcomes, by providing a faster, simpler and more successful launch process.
What EY can do for you
Biopharma launches set the tone for product lifecycle success. However, in this dynamic and uncertain environment, launches are often complex and fraught with increasing challenges, which explains why many of them underperform.
The EY Biopharma Launch Edge solution rewrites the rules to help deliver successful product launches. EY can help you and your organization deliver greater impact and get innovation to more patients faster, through the delivery of groundbreaking outcomes, step-change in engagement of others and unwavering confidence throughout.
The rapidly changing launch landscape
More than two out of three biopharma products launched since January 2020 have underperformed. About 38% of the products missed expectations by more than a 50% gap, according to the EY Commercial Launch Center of Excellence.
With the growing cost of drug development and reduced times to peak sales, getting a drug launch right is more critical than ever. The external factors that have added more complexity to the launch process include:
- Intensifying competition
- Rise of specialty drugs and advanced therapeutics that require a more bespoke launch
- Reduced engagement with stakeholders due to the COVID-19 pandemic and other factors
- Rising influence of payers
- Substantive health care reforms (e.g., Inflation Reduction Act)
- Need for omnichannel digital engagement with consumers and other stakeholders
Poor launch performance is often the result of inefficiencies at every stage of the prelaunch phase. Top internal factors include:
- Lack of visibility across functions and regions
- Inconsistent success metrics and tracking
- Low visibility of launch readiness at local levels
- Lack of alignment on strategy and execution, between global and local, and between clinical and commercial
- Huge volume of interdependent, preparatory activities
- Insufficient or delayed investment and resources
- Inconsistent execution
EY value creators
Why EY?
To deliver a successful drug product launch in today’s dynamic and challenging marketplace, you must reimagine your launch strategy and operations from the ground up. But you don’t have to do it alone. EY Biopharma Launch Edge provides you with the tools to plan, navigate, execute, and measure a strategic and sustaining launch. The results? Groundbreaking outcomes that deliver on sales expectations; a step-change in engagement of others, resulting in speedy mobilization and shared successes; and unwavering confidence throughout, delivering efficiencies relating to time, resources, and budget, and, ultimately, putting innovation in the hands of the patients.